The timing of COVID‐19‐related skin manifestations has been linked to the course of the disease: vesicular eruptions early in the disease (15% before other symptoms) and pseudo‐chilblain lesions late in the disease (59% after other symptoms). 3 The reported prevalence of cutaneous manifestations of COVID‐19 remains highly variable ( Box 2). 2 Other less frequent dermatological manifestations include oral mucosal signs, erythema multiforme‐like lesions, papulosquamous eruptions, dengue‐like rashes, and dry gangrene. 1 Subsequently, a systematic review of 46 articles found that the most commonly reported skin finding was chilblain‐like lesions (402, 40.2%), followed by maculopapular lesions (227, 22.7%), urticarial lesions (89, 8.9%), vesicular lesions (64, 6.4%), livedoid and necrotic lesions (28, 2.8%), and other or nondescript rashes and skin lesions (192, 19.8%). 1 A study of 1099 hospitalised patients in China found that cutaneous manifestations were only observed in two (0.2%) patients. The dermatological manifestations of COVID‐19 were first reported in April 2020. The loss of taste and smell persisted for ten weeks. The rash completely resolved by day 12 without further management, while other influenza‐like symptoms remained. The pruritus was successfully treated with an oral antihistamine on the advice of a dermatologist after topical moisturiser failed. On day 7, she developed headaches, palpations, subjective fevers and an eruption on the dorsum of her hands on day 8, the eruption became pruritic and had spread to her elbows, the dorsum of her feet, and chest ( Box 1). Five days after after symptom onset, she developed rhinorrhoea followed by loss of taste and smell (anosmia and ageusia).
0 Comments
Leave a Reply. |